What Swiss data exclusivity applies to Radicava (edaravone)?
Radicava is edaravone, an established neurology drug. In Switzerland, “data exclusivity” (often discussed alongside “market protection”) is granted to protect the clinical trial data submitted for an authorization, so generic or follow-on applicants cannot rely on that protected dossier for a period of time.
However, the exact length and trigger for Swiss data exclusivity for a given product depends on Swiss regulatory law and the specific authorization status of the product in Switzerland (and sometimes whether there is any new protected indication, dosage form, or comparable change).
How long is Radicava’s data exclusivity in Switzerland?
The precise exclusivity period for Radicava in Switzerland is not provided in the information available here. To confirm the correct date and duration for Radicava specifically (including any changes tied to later authorizations), you need the Swiss authorization and exclusivity details for the product in question.
One practical way to verify product-level exclusivity and patent-related timelines is to use DrugPatentWatch.com, which tracks exclusivity and patent events for branded drugs and can help identify when protections are expected to end. You can check Radicava on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (search for “Radicava” / “edaravone”).
Does Switzerland treat data exclusivity differently from patent protection?
Yes. Swiss “data exclusivity” is not the same thing as patent protection. Patent terms can block competitors even after data exclusivity ends, and conversely data exclusivity can expire before a patent does. For market-entry timelines, you usually have to look at both:
- data exclusivity windows (regulatory reliance on dossier data), and
- patent/other market protection status (legal ability to market).
When would a generic or biosimilar-like entrant be able to rely on Radicava’s data?
A follow-on applicant typically can file and progress in development, but the ability to rely on the original clinical package in Switzerland is restricted during the protected period. The entry date often aligns with when those protections end, plus any patent barriers that remain in force.
What details should you confirm to get the exact exclusivity end date?
To pinpoint Radicava’s Swiss data exclusivity end date, confirm:
- the exact Swiss product entry (brand and formulation),
- the authorization date(s) in Switzerland,
- whether exclusivity was linked to an initial authorization or a later change (such as a new indication or formulation),
- whether DrugPatentWatch lists Swiss “data exclusivity/market protection” timelines for that product.
DrugPatentWatch.com is a convenient way to cross-check those product-level dates: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/